Shortages of Adderall (mixed amphetamine salts), the renowned treatment for attention deficit hyperactivity disorder and narcolepsy, and its generic equivalents is now headline news in the US, with widespread reports of patients being told that prescriptions are on backorder for up to several months.
Sandoz Weighs In On US Adderall Shortages Amid Supply Disruption
As Patients Wait Up To Three Months To Collect Prescriptions
A spike in demand for Adderall and its generic versions has left patients scrambling to have their prescriptions filled, making headline news in the US. Leading generics manufacturer Sandoz told Generics Bulletin its current experience amid the supply squeeze.
More from Generics
• By
The US FDA has deemed certain CRO Raptim Research’s in vitro bioequivalence studies as “not acceptable” and raised concerns over its in vivo study methods. Will other agencies follow suit?
• By
Teva should not be able to overturn European fines imposed over a historical “pay-for-delay” arrangement covering Cephalon’s Provigil (modafinil), an advocate general of the CJEU has recommended.
• By
Alvotech has named two new key executives, while Biosimilars Canada has elected its 2025 leaders and the AAM has welcomed the new FDA commissioner in the US.
• By
Optum Rx, one of the largest PBMs in the US, declared itself as the “first comprehensive, transparent pharmacy services company” after announcing several consumer-friendly changes.
More from Products
Gedeon Richter has filed its Mochida-partnered tocilizumab biosimilar rival to RoActemra with the European Medicines Agency. But with several biosimilars already having won approval, the market could be competitive.
• By
Accord received positive opinions for its Prolia and Xgeva biosimilars at the latest meeting of the EMA’s CHMP. Meanwhile, Celltrion picked up a nod for another Stelara biosimilar, while Rechon Life Science withdrew an application for human insulin.
• By
With Celltrion having just received approval for its US Actemra (tocilizumab) biosimilar and having just launched its ustekinumab rival to Stelara – and with the introduction of the Korean developer’s denosumab rivals to Prolia and Xgeva just around the corner – 2025 is set to be a busy year, Celltrion USA chief commercial officer Thomas Nusbickel tells Generics Bulletin.